Loading...Loading...Shortly following the news on FDA's 'breakthrough therapy' designation and the 12-week clinical durability data on its LSD therapy for generalized anxiety, psychedelics biotech MindMed MNMD announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 each. The company has also entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares, at an individual price of $6.00.

正在加载。。。正在加载。。。在FDA的“突破疗法”指定消息和其用于广泛性焦虑的LSD疗法的12周临床耐久性数据发布后不久，迷幻药生物技术MindMed MNMD宣布以每股6美元的发行价格承销1666667股普通股，每股无面值。该公司还签订了股票购买协议，同时以6.00美元的个人价格私募12500000股普通股。

All these shares are being sold by MindMed to new investors Deep Track Capital and Commodore Capital.Meanwhile, the underwritten offering reportedly includes participation from new investors Ally Bridge Group, Driehaus Capital Management and Great Point Partners LLC, among several others.Leerink Partners and Cantor are acting as joint bookrunning managers for the underwritten offering and placement agents for the private placement.

所有这些股票都由MindMed出售给新投资者Deep Track Capital和Commodore Capital。与此同时，据报道，包销发行包括新投资者Ally Bridge Group、Driehaus Capital Management和Great Point Partners LLC等几家公司的参与。Leerink Partners和Cantor担任包销发行和私募配售代理的联合账簿管理人。

RBC Capital Markets is acting as lead manager for the underwritten offering and placement agent for the private placement.Total gross proceeds, from the underwritten offering and the concurrent private placement are expected to be around $175 million. Both non-contingent transactions are expected to close on or about March 11, 2024.

RBC Capital Markets担任私募承销发行和配售代理的首席管理人。包销发行和同期私募的总收益预计约为1.75亿美元。这两项非或有交易预计将于2024年3月11日左右完成。

The shares' distribution excludes Canada and Canadian residents.Equity Research AnalysisIn light of the latest favorable 12-week outcomes recently unveiled by MindMed on its Phase 2b clinical trial assessing the company's proprietary LSD drug for treating Generalized Anxiety Disorder (GAD,) senior analysts at Oppenheimer Equity Research have delivered a company update. .

股票分布不包括加拿大和加拿大居民。股票研究分析根据MindMed最近在其2b期临床试验中公布的最新有利的12周结果，该试验评估了该公司用于治疗广泛性焦虑症（GAD）的专有LSD药物，Oppenheimer Equity Research的高级分析师发布了公司最新消息。。

Results indicate a positive outlook for the company, with an outperform on stock rating; specifically pointing at:

结果表明，该公司前景乐观，股票评级表现出色；特别指出：

12-18 month price target set at $29.00 ($9.00 when the report was released, Thurs. 7, March 2024;)

12-18个月的价格目标定为29美元（报告发布时为9美元，2024年3月7日星期四；）

Market capitalization of $522.3 million;

市值5.223亿美元；

38 million shares outstanding;

3800万股流通股；

25 million float;

2500万浮动；

52-week range between $11.10 and $2.41;

52周的价格在11.10美元至2.41美元之间；

Average daily trading volume of 781,032;

日均交易量781032；

Book value of $4.38;

账面价值4.38美元；

Long-term debt of $14 million;

1400万美元的长期债务；

Common equity of a total $152 million.

普通股总计1.52亿美元。

Oppenheimer analysts said they are 'impressed' by the sustained improvement in anxiety symptoms at Week 12 and, given the successful Phase 2b trial, 'consider the upcoming two Phase 3 trials derisked as key design elements are expected to be consistent.' These elements include the primary endpoint (HAM-A at Week 4), minimal adjustments to inclusion/exclusion criteria, and unchanged patient-monitoring procedures.

奥本海默（Oppenheimer）分析师表示，他们对第12周焦虑症状的持续改善“印象深刻”，鉴于2b期试验的成功，“考虑到即将进行的两项被嘲笑为关键设计要素的3期试验预计会保持一致。”这些因素包括主要终点（第4周的HAM-A），对纳入/排除标准的最小调整以及不变的患者监测程序。

Phase 3 development is still expected to initiate in the second half of 2024. Loading...Loading...The research team also highlighted MindMed's LSD compound MM120 Orally Dissolving Tablet (ODT)s’ 'encouraging product profile' including the company's plans for use in Phase 3 trials. 'We are encouraged by its differentiated performance – compared to the capsule, MM120 ODT showed 50% quicker onset (faster absorption, shorter time to reach target concentrations), 17% increase in bioavailability, 23% higher AUC [total drug exposure over time] at the target concentration, and fewer GI [gastrointestinal] side effects,' the report reads. The team said that, commercially the Spravato model 'charts a promising path forward' for MM120, encouraged by market research reportedly indicating that 92% of Spravato providers are likely to refer patients for MM120, and 84% are likely to prescribe and administer it.In conclusion, the analysts say that, while many companies have emerged in the psychedelic field, they see MindMed as a leader, using 'a very systematic biotech approach and benefits from extensive encouraging data related to the use of LSD.' They advise investors that, beyond the recent positive Phase 2b readout and 12-week durability of MM-120 in GAD, while 'difficult to overstate the market opportunity in GAD alone,' they should also 'keep a close eye on the rest of the.

第三阶段开发预计仍将于2024年下半年启动。装载。。。正在加载。。。该研究团队还强调了MindMed的LSD化合物MM120口服溶解片（ODT）“令人鼓舞的产品概况”，包括该公司用于3期试验的计划。“我们对其差异化的表现感到鼓舞-与胶囊相比，MM120 ODT在目标浓度下起效快50%（吸收更快，达到目标浓度的时间更短），生物利用度提高17%，AUC（总药物暴露时间）提高23%，胃肠道副作用更少，”报告写道。该团队表示，在商业上，Spravato模式为MM120“描绘了一条有希望的前进道路”，据报道，市场研究表明，92%的Spravato提供者可能会为MM120转诊患者，84%的人可能会开处方并管理它。总之，分析人士说，虽然许多公司已经在迷幻药领域崭露头角，但他们认为MindMed是领导者，使用“非常系统的生物技术方法，并受益于与使用LSD有关的大量令人鼓舞的数据。”他们建议投资者，除了最近积极的2b期读数和MM-120在GAD中的12周耐久性之外，虽然“很难夸大GAD的市场机会”，但他们还应该“密切关注其余部分”。